Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN–JDRF Type 1 Diabetes Combination Therapy Assessment Group

JB Matthews, TP Staeva, PL Bernstein… - Clinical & …, 2010 - academic.oup.com
JB Matthews, TP Staeva, PL Bernstein, M Peakman, M Von Herrath
Clinical & Experimental Immunology, 2010academic.oup.com
Like many other complex human disorders of unknown aetiology, autoimmune-mediated
type 1 diabetes may ultimately be controlled via a therapeutic approach that combines
multiple agents, each with differing modes of action. The numerous advantages of such a
strategy include the ability to minimize toxicities and realize synergies to enhance and
prolong efficacy. The recognition that combinations might offer far-reaching benefits, at a
time when few single agents have yet proved themselves in well-powered trials, represents …
Summary
Like many other complex human disorders of unknown aetiology, autoimmune-mediated type 1 diabetes may ultimately be controlled via a therapeutic approach that combines multiple agents, each with differing modes of action. The numerous advantages of such a strategy include the ability to minimize toxicities and realize synergies to enhance and prolong efficacy. The recognition that combinations might offer far-reaching benefits, at a time when few single agents have yet proved themselves in well-powered trials, represents a significant challenge to our ability to conceive and implement rational treatment designs. As a first step in this process, the Immune Tolerance Network, in collaboration with the Juvenile Diabetes Research Foundation, convened a Type 1 Diabetes Combination Therapy Assessment Group, the recommendations of which are discussed in this Perspective paper.
Oxford University Press